BioSig Deploys Vuzix M400 Smart Glasses to Offer Remote Servicing Capabilities in Compliance with COVID-19 Travel Restriction...
January 13 2021 - 9:32AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced a partnership with Vuzix® Corporation
(NASDAQ: VUZI), a leading supplier of smart glasses and augmented
reality (AR) technology and products. BioSig will deploy Vuzix’s
M400 Smart Glasses for remote servicing of its PURE
EP™ System, supporting the planned nationwide rollout of
BioSig’s novel real-time signal processing platform to the
large and growing electrophysiology market in the U.S. The remote
servicing support offers an ideal solution for compliance with
COVID-19 travel restrictions.
“We are thrilled to work with Vuzix to deploy its outstanding
smart glasses solution and enhance our technology offering as we
work to accelerate commercialization of our PURE EP™ System
nationwide,” said Kenneth L. Londoner, Chairman & CEO of BioSig
Technologies, Inc. “The Vuzix M400s are the powerful enterprise
smart glasses and have compelling clinical applications for digital
healthcare. The addition of AR technology to our PURE
EP™ System solution should give us an even greater opportunity
to elevate the standard of care in the electrophysiology
market.”
The Vuzix M400 is the next evolution of the industry-leading
Vuzix M-Series smart glasses, featuring the new Qualcomm®
Snapdragon(TM) XR1 platform. Vuzix was hand-selected as one of the
initial launch partners for the new Snapdragon XR1 platform, the
first purposely built, dedicated XR platform from Qualcomm
Technologies. The Snapdragon XR1 microprocessor enables a
combination of voice and touchpad navigation for complete control
over the device. The M400 Smart Glasses improve processes within
many applications such as warehouse logistics, telemedicine,
manufacturing, and field service.
Equipped with Vuzix Remote Assist (VRA) software, the M400 Smart
Glasses should provide BioSig’s partner physicians and clinicians
with quick remote access to technical experts who can assist with
servicing the unique hardware architecture and digital
modality of PURE EP™ Systems being utilized in the field.
Enterprise use of the M400 Smart Glasses is intended to enable
technicians to support BioSig’s systems without the necessity of
on-site visits, dramatically decreasing time and expense for both
the Company and PURE EP™ System users.
BioSig plans to explore whether Vuzix Smart Glasses may be
used to facilitate remote customer training and provide
line-of-sight visualization of intracardiac signals during ablation
procedures performed by physicians. In the healthcare industry,
Vuzix Smart Glasses are already being used in hospitals and medical
centers around the world to perform a wide range of functions,
including training, virtual rounds within ICUs, triage in the
emergency room and the operating room to guide physicians during
surgery, and to provide remote training and mentor remote
doctors.
"BioSig’ PURE EP™ System is an incredibly innovative solution
that is tackling a tough problem, and we are proud to support this
promising product," said Paul Travers, President and Chief
Executive Officer of Vuzix. “Vuzix has deep experience working with
medical and healthcare providers to support applications that have
ranged from performing surgeries to telemedicine, patient care,
training, remote learning, and much more. We are happy to broaden
our support of the healthcare industry by entering the medical
device market, particularly the rapidly growing field of
bioelectronic medicine.” About Vuzix
Corporation Vuzix is a leading supplier of Smart-Glasses
and Augmented Reality (AR) technologies and products for the
consumer and enterprise markets. The Company's products include
personal display and wearable computing devices that offer users a
portable high-quality viewing experience, provide solutions for
mobility, wearable displays, and augmented reality. Vuzix holds 179
patents and patents pending and numerous IP licenses in the Video
Eyewear field. The Company has won Consumer Electronics Show (or
CES) awards for innovation for the years 2005 to 2020 and several
wireless technology innovation awards among others. Founded in
1997, Vuzix is a public company (NASDAQ: VUZI) with offices in
Rochester, NY, Oxford, UK, and Tokyo, Japan. For more information,
visit Vuzix website, Twitter and Facebook pages.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EPä System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024